/ September 26, 2009

New AIDS Vaccine Generates Helpful Questions

 

The new AIDS vaccine, RV 144 was declared a success after its six-year clinical trial.  Vaccinated volunteers contracted AIDS1/3 less often than those given a placebo.  This was welcome news after twenty years of vaccine failures.
So far, no one knows why the vaccine was marginally successful in the volunteer patients, but the hope is that researchers will be able to answer the new questions:
1.       Why did the vaccine work in some people but not in others?
2.       Why did were many of the patients who received the vaccine still infected?
These results represent the largest AIDS vaccine trial ever.  Over 16,000 Thai patients volunteered and the overall cost was $105 million.

Comments are closed.